Business

Sarepta Therapeutics PT Raised to $160 at BTIG 'on Our Conviction on SRP-9001's FDA Approval'

Sarepta Therapeutics PT Raised to $160 at BTIG 'on Our Conviction on SRP-9001's FDA Approval'

Blake

News and digital media editor, writer, and communications specialist. Passionate about social justice, equity, and wellness. Covering the news, viewing it differently.

Related Articles

Back to top button